PDMPs
Plasma Derived Medicinal Products PDMPs are essential Medicines derived from human plasma.
Diseases and disorders treated with Plasma Derived Medicinal Products:
Albumin
- Burns
- Liver failure
- Lung injury
- Major surgery
- Sepsis
- Shock
- Trauma
Alpha-I Proteinase Inhibitor Concentrate
- Alpha-1 antitrypsin deficiency
Clotting Factor Concentrates
- Antithrombin Ill deficiency
- Factor VII deficiency
- Fibrinogen deficiency
- Haptoglobin deficiency
- Hemophilia A
- Hemophilia B
- Thrombin deficiency
- Von Willebrand disease
Polyvalent Immune Globulin
- Primary Immunodeficiency diseases
- Secondary Immunodeficiency diseases
- Bone marrow transplant
- B-cell chronic lymphocytic leukemia
- Pediatric HIV
- Guillain Barré Syndrome
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Idiopathic Thrombocytopenic Purpura (ITP)
- Kawasaki disease
- Other auto-immune and inflammatory diseases
Hyper Immune Globulins
- Cytomegalovirus
- Hepatitis A
- Hepatitis B
- Respiratory Syncytial Virus (RSV)
- Rabies
- Anti-D to prevent Haemolytic Disease of the Newborn
- Tetanus
- Vaccinia
- Varicella Zoster
For further information please click here to access the article “Evidence-based clinical indications of plasma products and future prospects”, published 21 December 2017 in Annals of Blood.
Patients’ Safety
Patient safety underpins all activities of IPFA and its member organisations. Safety factors include product safety, access, security and affordability of supply and appropriate regulation.